Next Article in Journal
Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?
Next Article in Special Issue
In Vitro Efficacy of Essential Oils from Melaleuca Alternifolia and Rosmarinus Officinalis, Manuka Honey-based Gel, and Propolis as Antibacterial Agents Against Canine Staphylococcus Pseudintermedius Strains
Previous Article in Journal
A Novel Derivative of Thioridazine Shows Low Toxicity and Efficient Activity against Gram-Positive Pathogens
Previous Article in Special Issue
Genomic Characterization of Antimicrobial Resistance, Virulence, and Phylogeny of the Genus Ochrobactrum
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 9
Issue 6
10.3390/antibiotics9060328
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030

by
Manu Singh
1,
P. Malaka De Silva
1,
Yasser Al-Saadi
1,
Jacek Switala
1,
Peter C. Loewen
1,
Georg Hausner
1,
Wangxue Chen
2,
Ismael Hernandez
3,
Santiago Castillo-Ramirez
3 and
Ayush Kumar
1,*
1
Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
2
Human Health Therapeutics, National Research Council Canada, 100 Sussex Drive, Ottawa, ON K1A 0R6, Canada
3
Programa de Genómica Evolutiva, Centro de Ciencias Génomicas, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico
*
Author to whom correspondence should be addressed.
Antibiotics 2020, 9(6), 328; https://doi.org/10.3390/antibiotics9060328
Submission received: 17 May 2020 / Revised: 12 June 2020 / Accepted: 15 June 2020 / Published: 17 June 2020
(This article belongs to the Special Issue Bacterial Pathogens Resistance and Virulence)
Browse Figures
Versions Notes

Abstract

:
Acinetobacter baumannii is an important nosocomial bacterial pathogen. Multidrug-resistant isolates of A. baumannii are reported worldwide. Some A. baumannii isolates display resistance to nearly all antibiotics, making treatment of infections very challenging. As the need for new and effective antibiotics against A. baumannii becomes increasingly urgent, there is a need to understand the mechanisms of antibiotic resistance and virulence in this organism. In this work, comparative genomics was used to understand the mechanisms of antibiotic resistance and virulence in AB030, an extremely drug-resistant and hypervirulent strain of A. baumannii that is a representative of a recently emerged lineage of A. baumannii International Clone V. In order to characterize AB030, we carried out a genomic and phenotypic comparison with LAC-4, a previously described hyper-resistant and hypervirulent isolate. AB030 contains a number of antibiotic resistance- and virulence-associated genes that are not present in LAC-4. A number of these genes are present on mobile elements. This work shows the importance of characterizing the members of new lineages of A. baumannii in order to determine the development of antibiotic resistance and virulence in this organism.

1. Introduction

Acinetobacter baumannii infections are being reported with increasing frequency worldwide [1,2]. A. baumannii’s success as an important hospital-acquired pathogen is attributed to its ability to acquire and accumulate genes associated with antibiotic resistance. As a result, multidrug-resistant isolates of A. baumannii are commonly reported from various clinical settings [3,4,5]. Recently, the WHO categorized carbapenem-resistant A. baumannii as the top priority pathogen against which treatment options are urgently needed [6]. Understanding the mechanisms of resistance as well as how antibiotic resistance genes spread in clinical isolates of A. baumannii is critical for finding new and effective treatment options for antibiotic-resistant A. baumannii isolates. With recent advances in next-generation sequencing, comparative genomics has emerged as a powerful tool for understanding the mechanisms of antibiotic resistance and virulence in bacterial pathogens [7,8].
Recently, a lineage sequence type 758 (ST758) of A. baumannii belonging to the International Clone V has been described [9]. Isolates belonging to IC5 lineage have been reported from clinical settings in North and Central America [9], underscoring the need to characterize the isolates belonging to this lineage. A. baumannii AB030, an extremely drug-resistant (XDR) isolate, was one of the first members described from this lineage [10]. Due to its XDR phenotype as well as it being a member of recently emerging lineage, it was undertaken to characterize AB030 to gain insights into its antibiotic resistance and virulence mechanisms. Using a combination of comparative genomic and phenotypic approaches, genetic factors that contribute to its antibiotic resistance and virulence of AB030 were determined. The genome sequence of AB030 was compared to that of LAC-4, a previously described multidrug-resistant and hypervirulent isolate of A. baumannii [11]. Following comparative genomics analysis, phenotypic assays were carried out to interpret and confirm the in silico predictions.

2. Results and Discussion

A recent analysis [9] shows that AB030 is a member of a recently emerged lineage (ST758) belonging to the international clone V. AB030, isolated in Canada, shares a common ancestry with eight other isolates described from Mexico [9], indicating that ST758 is perhaps spreading in hospitals in the Americas. As such, characterization of members of ST758 is important to understand genotypic and phenotypic profiles of this lineage. We used LAC-4 for the comparison of AB030’s virulence and antibiotic resistance. LAC-4, although a member of ST10 that clusters separately from AB030, is a hyper-resistant and hypervirulent A. baumannii strain [11] and therefore serves as a good reference strain to determine the antibiotic resistance and virulence potential of AB030.

2.1. Genome Analysis

AB030’s chromosome is larger with 4,335,793 bp, compared to 3,954,354 bp in LAC-4 (Table 1). No plasmids were detected in AB030. LAC-4 has been previously shown to contain two plasmids [11].
Progressive Mauve alignment on these chromosomes (Figure 1a) highlights genomic rearrangements between these two strains and highlights the regions that add to the size of the genome of AB030 in comparison to LAC-4. Some of these differences are described later in this section.

2.2. Common Coding Sequences in AB030 and LAC-4

The AB030 genome contains 4200 CDS whereas LAC-4 contains 3745 CDS. Of these, 3012 CDS are common in AB030 and LAC-4 at ≥95% identity, while 1188 and 733 CDS are unique for AB030 and LAC-4, respectively (Figure 1b). Comparisons of functional categories according to the COG database for all CDS in these genomes are shown in Figure 2. The majority of these unique sequences are classified as either hypothetical proteins or phage elements. Amino acid sequence searches in the NCBI database of hypothetical proteins resulted in no significant hits (E-value = 1 × 106). The COG categories show that AB030 has more (1764) functionally uncharacterized CDS than LAC-4 (1346).

2.3. Genomic Islands, Phage Sequences, and Insertion Sequences

Antibiotic resistance of A. baumannii is often attributed to its ability to readily acquire resistance genes present in mobile DNA elements [12]. We analyzed and compared the presence of genomic islands, phage elements, and insertion sequences in AB030 and LAC-4.
Genomic islands (GIs) are large (>10 kb) genetic elements that contribute to fitness and adaptation of bacteria to various environmental conditions [13]. They can also carry genes for antibiotic resistance (resistance islands) as well as virulence (pathogenic islands) and therefore contribute to the rapid evolution of bacterial pathogens such as A. baumannii. Twelve different GIs have been described in LAC-4 [11]. The AB030 genome was analyzed for the presence of these 12 GIs. A summary of GIs from LAC-4 and their presence in AB030 is provided in Table 2 as well as in Figure S1a–l. Of the 12 reported GIs in LAC-4, GI1 (Figure S1a) is the only one that contains antibiotic resistance genes, those for streptomycin (strA and strB) and sulphonamide (sul2) resistance [11]. All of the genes present in this genomic island were 100% conserved in AB030, albeit the island in AB030 also contained two additional genes, cmlA and ISAba43. The rest of the genomic islands were present only in parts with the exception of GI2, which contained a 15-gene copper resistance cluster [11] in LAC-4 (Table 2 and Figure S1b) and GI8, which was completely missing from AB030. GI3 has been shown to contain AdeIJK efflux pump in LAC-4 [11]. This pump, which is constitutively expressed in A. baumannii, is also present in AB030 (Figure S1c). Overall, our data show that the GIs present in LAC-4 are largely absent in AB030.
Genomic island AbaR is considered a potential contributor to the multidrug-resistant (MDR) phenotype of A. baumannii [14]. It was first reported as a large island (86 kb) harboring multiple antibiotic resistance genes [15] including those that confer resistance to streptomycin, aminoglycosides, tetracycline, and chloramphenicol [16]. A subsequent study showed that AbaR genomic island is common among A. baumannii isolates and is present in two-thirds of all A. baumannii genomes sequenced [17]. Many variants of AbaR-type resistance islands are known to exist with most containing three or four resistance genes with a median length of 17.63 kb [17]. AbaR-type islands have a strong preference for the comM gene (ATP-dependent protease) in A. baumannii [18,19], however, the comM gene in both AB030 and LAC-4 did not contain any insertions. Since, on rare occasions, AbaR insertion can occur at other sites as well [17], we analyzed both genomes for the presence of genes (orf1, tniA, tniB, orf2, orf3) that constitute the backbone of AbaR. None of these five genes were present in AB030 or LAC-4. Therefore, our analysis shows that AbaR is not present in either of the two strains.
We also carried out an analysis to determine GIs unique to AB030 and found 27 different islands (Table S1) using IslandViewer 4 [20]. Parts of these islands were found to be present in LAC-4 as well. A large majority of these islands did not contain antibiotic resistance genes and only three of these were identified as resistance islands (Table S1). However, a careful analysis of the identified sequences showed that only two of these three contained antibiotic resistance genes. One island is GI1 (Table 2 and Figure S1a), and the other is ~9 kb (2,458,526-2,467,319 bp) in length, inserted in a gene encoding a hypothetical protein (IX87_RS12440). It harbors two aminoglycoside resistance genes (described below in the section for aminoglycosides) and a β-lactamase gene (Figure 3a) and is absent in LAC-4. The presence of this island has been previously reported in multidrug-resistant A. baumannii isolates AbH120-A2 from Spain [21] and AF-401 from Mexico [22] (Figure 3b). This island has also been shown to be present on a 65 kb IncN plasmid in Klebsiella pneumoniae KP1050 [23]. It has been suggested that K. pneumoniae KP1050 has acquired this from A. baumannii [23] (Figure 3b). In our study, the insertion sequence in this island was identified as that belonging to the IS6 family by IslandViewer (Figure 3a), however since IS26 is the most commonly studied member of the IS6 family [24], the insertion sequence in this island may very well be IS26.
ISfinder [25] was used to determine the presence of insertion sequences in AB030 and LAC-4. Several insertion sequences, distributed throughout the respective genomes, were found in both strains. AB030 contained 51 insertion sequences and LAC-4 contained 47 IS elements (Figure S2).
The presence of phage elements was predicted by the PHASTER server [26]. AB030 showed the presence of 14 prophage sequences compared to six in LAC-4. Of the 14 prophage sequences in AB030, five were intact, seven were incomplete, and two were questionable, whereas among the six prophage sequences found in LAC-4, one was intact, four were incomplete, and one was questionable (Table S2). Other than contributing to the larger genome size of AB030, we currently do not know what the significance of additional phage sequences in this strain is.

2.4. Antibiotic Susceptibility and Analysis of Antibiotic Resistance Genes

As shown in Table S3, AB030 is an extensive drug-resistant isolate that displays resistance to fluoroquinolones (levofloxacin), carbapenem (imipenem and meropenem), aminoglycosides (amikacin), and tigecycline. AB030, however, displays a much broader resistance profile to different classes of antibiotics than LAC-4 [27].
In order to identify genes potentially responsible for antibiotic resistance in AB030, its chromosome was analyzed along with the chromosome of LAC-4 using the Comprehensive Antibiotic Resistance Database (CARD) [28]. Details on the predicted genes are shown in Figure 4. Genes associated with resistance to different classes of antibiotics in AB030 and LAC-4 are described below.

2.4.1. Fluoroquinolones

Fluoroquinolone resistance in bacteria is a result of target mutations, such as those in GyrA and ParC [29], in addition to efflux. AB030 contains multiple mutations in both GyrA and ParC: GyrA (81S→L) and ParC (84S→L, 467S→G) (Figure 4). LAC-4, in comparison, contains 88E→K and 467S→G in ParC. Among different mutations seen in ParC, 84S→L and 88E→K have been shown to be important in quinolone resistance [30,31], whereas a mutation in GyrA alone generally leads to a modest decrease in susceptibility to quinolones [32]. Nevertheless, a combination of mutations in both ParC and GyrA often leads to clinically significant quinolone resistance [32]. AB030 and LAC-4 display similar susceptibility to ciprofloxacin but AB030 is > eight-fold less susceptible to levofloxacin than LAC-4. It has been shown that susceptibility to different fluoroquinolone antibiotics can differ dramatically in clinical isolates, likely because of differences in the structure of the drug [33]. Susceptibility to ciprofloxacin and levofloxacin also varies depending on the number of mutations in quinolone resistance-determining regions (QRDRs) of gyr and par genes. For example, E. coli and Klebsiella spp. mutations in 83S and 87D together have been shown to be associated with levofloxacin resistance while mutation in 83S alone has been associated with ciprofloxacin resistance [34]. It remains to be seen if differences in the mutations found in parC of AB030 and LAC-4 contribute to the lower susceptibility of AB030 to levofloxacin compared to LAC-4.

2.4.2. β-Lactams

AB030 is resistant to carbapenems: meropenem and imipenem [35]. Resistance to carbapenems is particularly concerning as these are considered the “last-resort” antibiotics for treatment of A. baumannii infections [36]. AB030’s resistance to carbapenems can be explained by the presence of blaOXA-65 and two copies of blaOXA-23 (IX87_RS16500 and IX87_RS21460) genes (Figure 4). These genes, absent in LAC-4, have been shown to confer resistance to carbapenems, specifically, meropenem and imipenem [37]. Interestingly, AB030 contains two copies of blaOXA-23. blaOXA-23 can be plasmid-borne or chromosomal and has been reported in both clinical and environmental isolates of A. baumannii [38,39]. In AB030, both copies of blaOXA-23 are flanked by ISAba1 insertion sequences. AB030 also contains blaOXA-65 while LAC-4 contains blaOXA-68. The genetic locations of these genes were identical in both isolates (Figure S3a). These two genes are classified as blaOXA-51-like and their products have a greater affinity for imipenem than meropenem [40]. Identity of each of the two genes was confirmed by sequence alignment with published sequences of blaOXA-65 and blaOXA-68 [41] (Figure S3b).
CARD analysis also showed the presence of ADC beta-lactamases in both AB030 and LAC-4 (Figure S4). ADC or Acinetobacter-derived cephalosporins are active against extended-spectrum cephalosporins but not against carbapenems [42]. AB030 contains blaADC-5 and LAC-4 contains blaADC-76. blaADC-5 has previously been reported in Acinetobacter pittii [43]. On the other hand, blaADC-76, found in LAC-4, is rare and has only been reported in one other clinical isolate of A. baumannii [44].

2.4.3. Aminoglycosides

Aminoglycoside resistance in A. baumannii is widely reported [45]. High levels of resistance is often attributed to the modification of aminoglycosides by acetyltransferases (AAC) [46]. AB030 contains several aminoglycoside resistance genes (Figure 4), including aac genes located on a mobile element (also described above in the section for beta-lactams) (Figure 3a,b). This mobile element, reported in two other multidrug-resistant A. baumannii strains, AbH12O-A2 [21] and AF-401 [22] (Figure 3b), contains aac(3)-IIa and aac(6’)-Ian that flank the beta-lactamase blaTEM-1. aac(3)-IIa confers resistance to gentamicin and has been reported in relatively few isolates of A. baumannii [47]. aac(6’)-Ian, on the other hand, is a novel amikacin resistance determinant reported recently in Serratia marcescens [48].
Both AB030 and LAC-4 also contain aminoglycoside phosphotransferase (APH)-encoding genes. Of these, APH(3”)-Ib and APH(6)-Id were found in both isolates and their transfer is potentially mediated by an ISAba1 element encoded upstream of APH(3”)-Ib (Figure S5).

2.4.4. Tigecycline

Tigecycline is an important antibiotic for the treatment of MDR A. baumannii infections [49]. AB030’s resistance to tigecycline (Table S3) indicates that treatment options for isolates such as AB030 are extremely limited. Lower susceptibility of AB030 to tigecycline can perhaps be explained via a point mutation 57V→L in RpsJ (30S ribosomal protein S10) (Figure 4). 57V→L in RpsJ mutation is shown to be quite frequent in A. baumannii isolates when exposed to tetracycline [50]. Further, expression of the AdeABC pump is an important determinant of tigecycline resistance in A. baumannii [51]. This pump is overexpressed in AB030 [35], which may also at least be partially responsible for AB030’s resistance to tigecycline. Expression of the AdeABC system is activated by a two-component system AdeRS [52]. LAC-4 is missing the adeRS operon in its entirety (Figure 4 and Figure 5). We did not analyze the expression of AdeABC in LAC-4 and it is not clear what impact the absence of the adeRS operon has on the expression of the AdeABC pump.

2.5. Virulence of A. baumannii Strains in Mouse Infection Model and Analysis of Virulence Genes

Genes associated with virulence factors in AB030 and LAC-4 are summarized in Table S3. As is evident from the table, AB030 harbors more virulence-associated genes compared to LAC-4. In order to test the virulence of AB030, the intranasal mice infection model was used [27]. Dissemination of AB030 to lung, spleen, and blood was assessed after 24 h of infection as a determinant of pathogenicity. A. baumannii ATCC17978 was used as the control. As shown in Figure 6a–c, AB030 was as efficient as LAC-4 in colonizing lungs, spleen, and blood of the infected mice. However, the clinical outcome of mice infected with AB030 was slightly poorer than that for LAC-4, indicating that AB030 may be more virulent than LAC-4 (Figure 6d). These data show that in addition to being hyper-resistant to antibiotics, AB030 is also hypervirulent.
Following the confirmation of the hypervirulent phenotype, AB030 was tested for specific virulence-associated phenotypes, such as biofilm formation, motility, and catalase activity. These phenotypes were chosen based on the underlying genetic differences among these strains as listed in Table S4.
Biofilm formation is an important virulence factor in pathogenic bacteria [53]. It can result in persistent, difficult-to-eradicate infections. We observed that AB030 was more efficient in forming biofilm compared to LAC-4 (Figure 7a) but less efficient than the type strain ATCC17978. Bap protein has been shown to be essential for biofilm formation in A. baumannii and is involved in biotic surface adherence [54]. bapA in AB030 is flanked by the ISAba27 insertion element. In Staphylococcus aureus, SarA protein has been shown to activate the expression of bap by binding to the promoter region [55]. While no such activator of bapA expression has been shown in A. baumannii, it is possible that the insertion in the promoter region of bapA in AB030 affects its expression and is likely to impact the biofilm formation (Figure 7b). Another factor suggested to be modulating biofilm in A. baumannii is the availability of iron for the cell. An increased biofilm formation has been observed in A. baumannii ATCC19606 in the absence of iron [56], similar observations have been reported in Pseudomonas aeruginosa [57]. However, a recent study failed to establish a clear link between iron availability and biofilm formation in veterinary and clinical isolates of A. baumannii [58]. Nevertheless, we did not find any obvious differences in the set of iron uptake genes in AB030 and LAC-4 (Supplementary Table S3) which may result in higher biofilm formation. LAC-4 was found to form little or no biofilm (Figure 7a). LAC-4 contains cryptic bap (Figure 7b) and therefore the factors leading to its inability to produce biofilms are perhaps similar to those of AB030. However, in addition to the disrupted bap, LAC-4 lacks abaI (LuxI synthase) and abaR (LuxR receptor) genes (Supplementary Table S3), both of which are part of the quorum sensing system in A. baumannii [59] and mutational inactivation of abaI has been shown to result in up to 40% reduction in biofilm formation in A. baumannii strains [60].
Motility is also considered an important virulence factor in bacteria [61]. Since A. baumannii lacks any flagellar structure, its surface motility (twitching) is mediated through pili [61,62]. The pili-mediated motility requires surface attachments which are provided by the proteins encoded by the csuABCDE operon [56]. AB030 and LAC-4 both did not display any motility on the agarose medium (Figure 8a). An analysis of the csu operon revealed that even though AB030 contains the intact csu operon (organized in identical fashion as in ATCC17978), it has insertions of ISAba1 and ISAba27, which are not present in ATCC17978, immediately upstream of the operon (Figure 8b). A two-component system CheA/Y has been shown to upregulate the expression of the csu operon [63] and the presence of the insertion elements upstream of the csu operon may impact its expression as mediated by the CheA/Y system. This may explain lack of motility observed in AB030 (Figure 8a). LAC-4, on the other hand, lacks the entire csu operon (Figure 8b), which may explain its lack of motility on agarose medium (Figure 8a).
The presence of catalase has been linked to bacterial pathogens’ resistance to host immune factors that employ reactive oxygen species such as hydrogen peroxide [64]. Both AB030 and LAC-4 displayed an increased catalase activity compared to ATCC17978, with AB030 showing the higher activity (Figure S6). In A. baumannii, KatG and KatE are the predominant catalases [65]. In addition, KatA and KatX have been described in Acinetobacter but their role in H2O2 resistance is not clear [65]. AB030 also contained katA, in addition to katG and katE (Table S4). This may explain slightly higher catalase activity observed in AB030, which may partially aid its hypervirulence.

3. Materials and Methods

3.1. Bacterial Strains and Growth Conditions

Two clinical isolates of A. baumannii, AB030 (NZ_CP009257.1) [10] and LAC-4 (NZ_CP007712.1) [11], were used in this study. Annotation of both these strains has been carried out automatically with the National Center for Biotechnology Information (NCBI) Prokaryotic Genome Annotation Pipeline (PGAP). ATCC17978 was used as the control strain. Bacterial strains were grown in LB broth (Becton, Dickenson and Company, MD, USA) at 37 °C with 250 rpm shaking unless otherwise stated.

3.2. Genome Alignment and Functional Assignation Analysis

Genomic rearrangements between AB030 and LAC-4 sequences were visualized by performing progressive Mauve aligner [66] with the Geneious software (version 11.0) [67] utilizing default parameters. GView server (https://server.gview.ca/) at 95% identity was used to compare the genomes of these two isolates. Comparative genome visualization was performed with CloVR version 1.0-RC9 [68]. All the annotated protein-coding sequences (CDS) from the above genomes were cross-referenced for orthologous sequences in the Clusters of Orthologous Groups (COG) database available in the NCBI CDD web search tool [69].

3.3. Genomic Islands, Phage Sequences, and Insertion Sequences

Insertion sequences in the two genomes were identified using ISfinder, a web-based tool which searches for insertion sequences in provided nucleotide sequences based on the sequences in their database [25]. The insertion sequences were considered a positive “hit” when their E-value was recorded below 0.01. Phage elements were identified using the PHASTER database [26]. Pathogenic islands were identified using the IslandViewer 4 database [20].

3.4. Antibiotic Susceptibility and Prediction of Antibiotic Resistance Genes

Antibiotic susceptibility for AB030 and LAC-4 have been published previously [11,35]. Antibiotic resistance genes were predicted using the Comprehensive Antibiotic Resistance Database (CARD) with “strict” and “perfect” parameters [28] using the genomes of AB030 (NZ_CP009257.1) and LAC-4 (NZ_CP007712.1). The presence/absence of predicted antibiotic resistance genes in three genomes were confirmed by searching the nucleotide sequences in the respective genomes using the BLASTn tool available in the NCBI server.

3.5. Identification of Virulence Genes

Genes encoding virulence factors were identified using the virulence factor (VF) analyzer online tool [70]. Presence and absence of virulence genes in three genomes were confirmed by searching nucleotide sequences in respective genomes using the BLASTn tool available in the NCBI server.

3.6. Intranasal A. baumannii Infection Assay

Adult (20–22 weeks old) pathogen-free female BALB/c mice were purchased from Charles River Laboratories (St. Constant, QC, Canada). The mice were maintained and used in accordance with the recommendations of the Canadian Council on Animal Care Guide to the Care and Use of Experimental Animals. All experimental protocols and procedures were approved by the institutional animal care committee, Human Health Therapeutics, National Research Council Canada (Animal User Protocol #2016.11).
Intranasal mice infection assays in female BALB/c mice were carried out as previously described [27]. Briefly, mice were anesthetized by intraperitoneal (i.p.) injection of 4% isoflurane with medical O2 and then inoculated intranasally with 5 × 107 CFU A. baumannii ATCC17978 and AB030 from fresh inocula in 50 μL of saline. Actual inocula in each experiment were determined by plating 10-fold serial dilutions on brain heart infusion agar plates. The clinical appearance of the mice was monitored and scored as described previously [27]. Groups of five infected mice were sacrificed 24 h post-inoculation (hpi). Quantitative bacteriology was carried out from lungs, spleens, and blood after their removal aseptically. Data obtained for ATCC17978 and AB030 were compared with data for LAC-4 obtained using a total of 18 mice (inoculum size of 2–6 × 107) from four experiments carried out on separate days from those for ATCC17978 and AB030.

3.7. Biofilm Assay

Biofilm formation was assayed based on a previously described method [71] with slight modifications. Briefly, bacterial strains were grown in 3 mL cultures overnight at 37 °C with 250 rpm shaking in LB broth (Becton, Dickenson and Company, MD, USA). The overnight cultures were then diluted 1:100 (v/v) in the same medium and 100 µL aliquots were distributed in individual wells of a 96-well round-bottom microplate (Sarstedt, Montréal, QC, Canada). The 96-well plates were then incubated at 37 °C in a static incubator for 48 h to allow the biofilm formation following which A600 was measured to determine the growth of the cultures using a SpectraMax M2 (Molecular Devices, San Jose, CA, USA). The culture medium and planktonic cells were removed by inverting the plates and washing wells twice with dH2O. One hundred µL of 0.5% (w/v) crystal violet was then added to each well and plates incubated for 20 min at room temperature before removing the crystal violet and repeating the washing as described above. Finally, to quantify the biofilm, 100 µL of acetone:ethanol (2:1) mixture was added to each well and incubated for 20 min and A580 determined. Biofilm formation was calculated by normalizing the A580 value with the A600 value for each well, plotted and statistically analyzed using GraphPad Prism v6.07 (La Jolla, CA, USA). The assays were carried out in biological duplicates with 16 technical replicates for each biological replicate.

3.8. Motility Assay

The surface motility was assayed based on a previously described method [62] using 0.3% agarose plates for each strain with slight modifications. Briefly, 3 µL of the overnight cultures of each strain were stab inoculated onto the center of freshly prepared 0.3% agarose plates and incubated for 18 h at 37 °C. The diameter of the region showing bacterial growth was measured after the incubation period and representative plates were photographed. Results were plotted and statistically analyzed using GraphPad Prism v6.07 (La Jolla, CA, USA). The assays were carried out with 10 biological replicates.

3.9. Catalase Activity Assay

Bacterial strains were grown overnight at 37 °C with 250 rpm shaking in LB broth into lag phase prior to the assay in a total volume of 5 mL in a 50 mL conical tube (Sarstedt, Montréal, QC, Canada). Absorbance at 600 nm was measured prior to the assay for the purpose of normalization of the catalase activity based on the growth of each strain. The catalase activity assay was carried out using a Gilson oxygraph equipped with a Clark electrode as described previously [72]. The assay was carried out in biological duplicates and the average values with the standard deviations were plotted and statistically analyzed using GraphPad Prism v6.07 (La Jolla, CA, USA).

4. Conclusions

In summary, this study shows that genome plasticity and accumulation of resistance genes via insertion elements contribute to the extreme drug resistance phenotype of A. baumannii AB030, a member of the newly emerging lineage of A. baumannii. Genomic and phenotypic comparison of AB030 with LAC-4 shows that AB030 has accumulated a number of genes that may contribute to its hyper-resistance and hypervirulence. Our data also show that biofilm formation on an abiotic surface and motility on agarose medium did not impact the virulence of AB030 and LAC-4 in mice models. This underscores the importance of other factors in the hypervirulence of AB030. Even though this work is limited to only one isolate of ST758 lineage and currently it is not clear if the other members of this lineage share the same phenotype as AB030, it highlights the importance of characterization of members of emerging lineages of A. baumannii for their virulence and antibiotic resistance.

Supplementary Materials

The following are available online at https://www.mdpi.com/2079-6382/9/6/328/s1, Figure S1. Alignment of genomic islands (GIs) described in A. baumannii LAC-4 [11] with those in A. baumannii AB030. Figure S2. Insertion Sequence (IS regions) in AB030 and LAC-4 genomes as predicted by ISfinder. Presence of the IS region is indicated by red and the absence by blue. Figure S3. Presence of blaOXA in A. baumannii AB030 and LAC-4 and alignment of each of the three genes with published sequences of blaOXA-65 and blaOXA-68 [41]. Figure S4. Presence of blaADC in A. baumannii AB030 and LAC-4. Figure S5. Presence of aminoglycoside phosphotransferase (APH)-encoding genes APH(3″)-Ib and APH(6)-Id in A. baumannii AB030 and LAC-4. Figure S6. Catalase activity of AB030 and LAC-4, in comparison to ATCC 17978. Table S1. Predicted genomic islands present in AB030 as identified by Islandviewer. Table S2. Predictions for the presence of phage elements in the genomes of AB030 and LAC-4. Table S3. Antibiotic susceptibility (μg/mL) assay of AB030 and LAC-4. Table S4. Presence of virulence genes in AB030 and LAC-4.

Author Contributions

Conceptualization, A.K., G.H., W.C. and S.C.-R.; methodology, M.S., P.M.D.S., Y.A.-S., J.S., P.C.L., A.K.; software, M.S.; G.H., I.H., S.C.-R. and A.K; validation, M.S., G.H., W.C., S.C.-R. and A.K.; software, M.S.; G.H., I.H., S.C.-R., A.K.; formal analysis, M.S., G.H., W.C., S.C.-R. and A.K.; resources, A.K.; data curation, M.S. and A.K.; writing—original draft preparation, M.S.; writing—review and editing, M.S., G.H., S.C.-R. and A.K.; supervision, A.K.; project administration, A.K.; funding acquisition, A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a Discovery Grant (2015-05550) from the Natural Science and Engineering Research Council (NSERC) of Canada to AK. MS and MDS were supported by scholarships from the Faculty of Science, University of Manitoba.

Acknowledgments

The authors would like to acknowledge Abdullah Zubaer for critical comments on the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Antunes, L.C.; Visca, P.; Towner, K.J. Acinetobacter baumannii: Evolution of a global pathogen. Pathog. Dis. 2014, 71, 292–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Howard, A.; O’Donoghue, M.; Feeney, A.; Sleator, R.D. Acinetobacter baumannii: An emerging opportunistic pathogen. Virulence 2012, 3, 243–250. [Google Scholar] [CrossRef] [PubMed]
  3. Apisarnthanarak, A.; Mundy, L.M. Mortality associated with pandrug-resistant Acinetobacter baumannii infections in Thailand. Am. J. Infect. Control 2009, 37, 519–520. [Google Scholar] [CrossRef] [PubMed]
  4. Bonnin, R.A.; Rotimi, V.O.; Hubail, M.A.; Gasiorowski, E.; Sweih, N.A.; Nordmann, P.; Poirel, L. Wide dissemination of GES-type carbapenemases in Acinetobacter baumannii isolates in Kuwait. Antimicrob. Agents Chemother. 2013, 57, 183–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Chan, P.C.; Huang, L.M.; Lin, H.C.; Chang, L.Y.; Chen, M.L.; Lu, C.Y.; Lee, P.I.; Chen, J.M.; Lee, C.Y.; Pan, H.J.; et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect. Control Hosp. Epidemiol. 2007, 28, 423–429. [Google Scholar] [CrossRef]
  6. World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/ (accessed on 10 April 2020).
  7. Di Nocera, P.P.; Rocco, F.; Giannouli, M.; Triassi, M.; Zarrilli, R. Genome organization of epidemic Acinetobacter baumannii strains. BMC Microbiol. 2011, 11, 224. [Google Scholar] [CrossRef] [Green Version]
  8. Farrugia, D.N.; Elbourne, L.D.; Hassan, K.A.; Eijkelkamp, B.A.; Tetu, S.G.; Brown, M.H.; Shah, B.S.; Peleg, A.Y.; Mabbutt, B.C.; Paulsen, I.T. The complete genome and phenome of a community-acquired Acinetobacter baumannii. PLoS ONE 2013, 8, e58628. [Google Scholar] [CrossRef] [Green Version]
  9. Graña-Miraglia, L.; Evans, B.A.; López-Jácome, L.E.; Hernández-Durán, M.; Colín-Castro, C.A.; Volkow-Fernández, P.; Cevallos, M.A.; Franco-Cendejas, R.; Castillo-Ramírez, S. Origin of OXA-23 variant OXA-239 from a recently emerged lineage of Acinetobacter baumannii International Clone V. mSphere 2020, 5, e00801-19. [Google Scholar] [CrossRef]
  10. Loewen, P.C.; Alsaadi, Y.; Fernando, D.; Kumar, A. Genome sequence of an extremely drug-resistant clinical isolate of Acinetobacter baumannii strain AB030. Genome Announc. 2014, 2, e01035-14. [Google Scholar] [CrossRef] [Green Version]
  11. Ou, H.-Y.; Kuang, S.N.; He, X.; Molgora, B.M.; Ewing, P.J.; Deng, Z.; Osby, M.; Chen, W.; Xu, H.H. Complete genome sequence of hypervirulent and outbreak-associated Acinetobacter baumannii strain LAC-4: Epidemiology, resistance genetic determinants and potential virulence factors. Sci. Rep. 2015, 5, 8643. [Google Scholar] [CrossRef]
  12. Doi, Y.; Murray, G.L.; Peleg, A.Y. Acinetobacter baumannii: Evolution of antimicrobial resistance—Treatment options. Semin. Respir. Crit. Care Med. 2015, 36, 85–98. [Google Scholar] [PubMed] [Green Version]
  13. Dobrindt, U.; Hochhut, B.; Hentschel, U.; Hacker, J. Genomic islands in pathogenic and environmental microorganisms. Nat. Rev. Microbiol. 2004, 2, 414–424. [Google Scholar] [CrossRef] [PubMed]
  14. Bonnin, R.A.; Poirel, L.; Nordmann, P. AbaR-type transposon structures in Acinetobacter baumannii. J. Antimicrob. Chemother. 2012, 67, 234–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Fournier, P.E.; Vallenet, D.; Barbe, V.; Audic, S.; Ogata, H.; Poirel, L.; Richet, H.; Robert, C.; Mangenot, S.; Abergel, C.; et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006, 2, e7. [Google Scholar] [CrossRef] [Green Version]
  16. Post, V.; White, P.A.; Hall, R.M. Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2010, 65, 1162–1170. [Google Scholar] [CrossRef] [Green Version]
  17. Bi, D.; Xie, R.; Zheng, J.; Yang, H.; Zhu, X.; Ou, H.-Y.; Wei, Q. Large-scale identification of AbaR-Type genomic islands in Acinetobacter baumannii reveals diverse insertion sites and clonal lineage-specific antimicrobial resistance gene profiles. Antimicrob. Agents Chemother. 2019, 63, e02526-18. [Google Scholar] [CrossRef] [Green Version]
  18. Kochar, M.; Crosatti, M.; Harrison, E.M.; Rieck, B.; Chan, J.; Constantinidou, C.; Pallen, M.; Ou, H.Y.; Rajakumar, K. Deletion of TnAbaR23 results in both expected and unexpected antibiogram changes in a multidrug-resistant Acinetobacter baumannii strain. Antimicrob. Agents Chemother. 2012, 56, 1845–1853. [Google Scholar] [CrossRef] [Green Version]
  19. Krizova, L.; Dijkshoorn, L.; Nemec, A. Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I. Antimicrob. Agents Chemother. 2011, 55, 3201–3206. [Google Scholar] [CrossRef] [Green Version]
  20. Bertelli, C.; Laird, M.R.; Williams, K.P.; Simon Fraser University Research Computing Group; Lau, B.Y.; Hoad, G.; Winsor, G.L.; Brinkman, F.S.L. IslandViewer 4: Expanded prediction of genomic islands for larger-scale datasets. Nucleic Acids Res. 2017, 45, W30–W35. [Google Scholar] [CrossRef]
  21. Merino, M.; Alvarez-Fraga, L.; Gomez, M.J.; Aransay, A.M.; Lavin, J.L.; Chaves, F.; Bou, G.; Poza, M. Complete genome sequence of the multiresistant Acinetobacter baumannii Strain AbH12O-A2, isolated during a large outbreak in Spain. Genome Announc. 2014, 2, e01182-14. [Google Scholar] [CrossRef] [Green Version]
  22. Higgins, P.G.; Pérez-Llarena, F.J.; Zander, E.; Fernández, A.; Bou, G.; Seifert, H. OXA-235, a novel cass D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2013, 57, 2121–2126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Lázaro-Perona, F.; Sotillo, A.; Troyano-Hernáez, P.; Gómez-Gil, R.; de la Vega-Bueno, Á.; Mingorance, J. Genomic path to pandrug resistance in a clinical isolate of Klebsiella pneumoniae. Int. J. Antimicrob. Agents 2018, 52, 713–718. [Google Scholar] [CrossRef] [PubMed]
  24. Harmer, C.J.; Hall, R.M. An analysis of the IS6/IS26 family of insertion sequences: Is it a single family? Microb. Genom. 2019, 5, e000291. [Google Scholar] [CrossRef] [PubMed]
  25. Siguier, P.; Perochon, J.; Lestrade, L.; Mahillon, J.; Chandler, M. ISfinder: The reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006, 34, D32–D36. [Google Scholar] [CrossRef] [Green Version]
  26. Arndt, D.; Grant, J.R.; Marcu, A.; Sajed, T.; Pon, A.; Liang, Y.; Wishart, D.S. PHASTER: A better, faster version of the PHAST phage search tool. Nucleic Acids Res. 2016, 44, W16–W21. [Google Scholar] [CrossRef] [Green Version]
  27. Harris, G.; Lee, R.K.; Lam, C.K.; Kanzaki, G.; Patel, G.B.; Xu, H.H.; Chen, W. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob. Agents Chemother. 2013, 57, 3601–3613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Jia, B.; Raphenya, A.R.; Alcock, B.; Waglechner, N.; Guo, P.; Tsang, K.K.; Lago, B.A.; Dave, B.M.; Pereira, S.; Sharma, A.N.; et al. CARD 2017: Expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 2017, 45, D566–D573. [Google Scholar] [CrossRef]
  29. Piddock, L.J. Mechanisms of fluoroquinolone resistance: An update 1994–1998. Drugs 1999, 58, 11–18. [Google Scholar] [CrossRef]
  30. Valentine, S.C.; Contreras, D.; Tan, S.; Real, L.J.; Chu, S.; Xu, H.H. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J. Clin. Microbiol. 2008, 46, 2499–2507. [Google Scholar] [CrossRef] [Green Version]
  31. Bagel, S.; Hüllen, V.; Wiedemann, B.; Heisig, P. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob. Agents Chemother. 1999, 43, 868–875. [Google Scholar] [CrossRef] [Green Version]
  32. Jacoby, G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 2005, 41 (Suppl. S2), S120–S126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Boyd, L.B.; Maynard, M.J.; Morgan-Linnell, S.K.; Horton, L.B.; Sucgang, R.; Hamill, R.J.; Jimenez, J.R.; Versalovic, J.; Steffen, D.; Zechiedrich, L. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 2009, 53, 229–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Drago, L.; Nicola, L.; Mattina, R.; De Vecchi, E. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. BMC Microbiol. 2010, 10, 119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Fernando, D.; Zhanel, G.G.; Kumar, A. Antibiotic resistance and expression of resistance-nodulation-division pumps and outer membrane porins in Acinetobacter species isolated from Canadian hospitals. Can. J. Infect. Dis. Med. Microbiol. 2013, 24, 17–21. [Google Scholar] [CrossRef] [PubMed]
  36. Pogue, J.M.; Mann, T.; Barber, K.E.; Kaye, K.S. Carbapenem-resistant Acinetobacter baumannii: Epidemiology, surveillance and management. Exp. Rev. Anti-Infect. Ther. 2013, 11, 383–393. [Google Scholar] [CrossRef] [PubMed]
  37. Lopes, B.S.; Al-Hassan, L.; Amyes, S.G. ISAba825 controls the expression of the chromosomal bla(OXA-51-like) and the plasmid borne bla(OXA-58) gene in clinical isolates of Acinetobacter baumannii isolated from the USA. Clin. Microbiol. Infect. 2012, 18, E446–E451. [Google Scholar] [CrossRef] [Green Version]
  38. Girlich, D.; Poirel, L.; Nordmann, P. First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. Antimicrob. Agents Chemother. 2010, 54, 578–579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Merino, M.; Poza, M.; Roca, I.; Barba, M.J.; Sousa, M.D.; Vila, J.; Bou, G. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain. Microb. Drug Resist. 2014, 20, 259–263. [Google Scholar] [CrossRef] [PubMed]
  40. Peleg, A.Y.; Seifert, H.; Paterson, D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008, 21, 538–582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Brown, S.; Amyes, S.G.B. The sequences of seven class D b-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clin. Microbiol. Infect. 2005, 11, 326–329. [Google Scholar] [CrossRef] [Green Version]
  42. Hujer, K.M.; Hamza, N.S.; Hujer, A.M.; Perez, F.; Helfand, M.S.; Bethel, C.R.; Thomson, J.M.; Anderson, V.E.; Barlow, M.; Rice, L.B.; et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: Defining a unique family of class C enzymes. Antimicrob. Agents Chemother. 2005, 49, 2941–2948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Beceiro, A.; Dominguez, L.; Ribera, A.; Vila, J.; Molina, F.; Villanueva, R.; Eiros, J.M.; Bou, G. Molecular characterization of the gene encoding a new AmpC β-lactamase in a clinical strain of Acinetobacter Genomic Species 3. Antimicrob. Agents Chemother. 2004, 48, 1374–1378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Karah, N.; Dwibedi, C.K.; Sjöström, K.; Edquist, P.; Johansson, A.; Wai, S.N.; Uhlin, B.E. Novel aminoglycoside resistance transposons and transposon-derived circular forms detected in carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob. Agents Chemother. 2016, 60, 1801–1818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Nigro, S.J.; Post, V.; Hall, R.M. Aminoglycoside resistance in multiply antibiotic-resistant Acinetobacter baumannii belonging to global clone 2 from Australian hospitals. J. Antimicrob. Chemother. 2011, 66, 1504–1509. [Google Scholar] [CrossRef] [Green Version]
  46. Davies, J.; Wright, G.D. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol. 1997, 5, 234–240. [Google Scholar] [CrossRef]
  47. Akers, K.S.; Chaney, C.; Barsoumian, A.; Beckius, M.; Zera, W.; Yu, X.; Guymon, C.; Keen, E.F., 3rd; Robinson, B.J.; Mende, K.; et al. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J. Clin. Microbiol. 2010, 48, 1132–1138. [Google Scholar] [CrossRef] [Green Version]
  48. Jin, W.; Wachino, J.; Kimura, K.; Yamada, K.; Arakawa, Y. New plasmid-mediated aminoglycoside 6’-N-acetyltransferase, AAC(6’)-Ian, and ESBL, TLA-3, from a Serratia marcescens clinical isolate. J. Antimicrob. Chemother. 2015, 70, 1331–1337. [Google Scholar] [CrossRef] [Green Version]
  49. Liou, B.-H.; Lee, Y.-T.; Kuo, S.-C.; Liu, P.-Y.; Fung, C.-P. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure. Antimicrob. Agents Chemother. 2015, 59, 3637–3640. [Google Scholar] [CrossRef] [Green Version]
  50. Hammerstrom, T.G.; Beabout, K.; Clements, T.P.; Saxer, G.; Shamoo, Y. Acinetobacter baumannii repeatedly evolves a hypermutator phenotype in response to tigecycline that effectively surveys evolutionary trajectories to resistance. PLoS ONE 2015, 10, e0140489. [Google Scholar] [CrossRef]
  51. Hornsey, M.; Ellington, M.J.; Doumith, M.; Thomas, C.P.; Gordon, N.C.; Wareham, D.W.; Quinn, J.; Lolans, K.; Livermore, D.M.; Woodford, N. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J. Antimicrob. Chemother. 2010, 65, 1589–1593. [Google Scholar] [CrossRef] [Green Version]
  52. Yoon, E.-J.; Courvalin, P.; Grillot-Courvalin, C. RND-Type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: Major role for AdeABC overexpression and AdeRS mutations. Antimicrob. Agents Chemother. 2013, 57, 2989–2995. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002, 15, 167–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Goh, H.M.; Beatson, S.A.; Totsika, M.; Moriel, D.G.; Phan, M.D.; Szubert, J.; Runnegar, N.; Sidjabat, H.E.; Paterson, D.L.; Nimmo, G.R.; et al. Molecular analysis of the Acinetobacter baumannii biofilm-associated protein. Appl. Environ. Microbiol. 2013, 79, 6535–6543. [Google Scholar] [CrossRef] [Green Version]
  55. Trotonda, M.P.; Manna, A.C.; Cheung, A.L.; Lasa, I.; Penadés, J.R. SarA positively controls bap-dependent biofilm formation in Staphylococcus aureus. J. Bacteriol. 2005, 187, 5790–5798. [Google Scholar] [CrossRef] [Green Version]
  56. Tomaras, A.P.; Dorsey, C.W.; Edelmann, R.E.; Actis, L.A. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: Involvement of a novel chaperone-usher pili assembly system. Microbiology 2003, 149, 3473–3484. [Google Scholar] [CrossRef] [Green Version]
  57. Wiens, J.R.; Vasil, A.I.; Schurr, M.J.; Vasil, M.L. Iron-regulated expression of alginate production, mucoid phenotype, and biofilm formation by Pseudomonas aeruginosa. mBio 2014, 5, e01010-13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Gentile, V.; Frangipani, E.; Bonchi, C.; Minandri, F.; Runci, F.; Visca, P. Iron and Acinetobacter baumannii biofilm formation. Pathogens 2014, 3, 704–719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Bhargava, N.; Sharma, P.; Capalash, N. Quorum sensing in Acinetobacter: An emerging pathogen. Crit. Rev. Microbiol. 2010, 36, 349–360. [Google Scholar] [CrossRef] [PubMed]
  60. Gaddy, J.A.; Actis, L.A. Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol. 2009, 4, 273–278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Eijkelkamp, B.A.; Stroeher, U.H.; Hassan, K.A.; Papadimitrious, M.S.; Paulsen, I.T.; Brown, M.H. Adherence and motility characteristics of clinical Acinetobacter baumannii isolates. FEMS Microbiol. Lett. 2011, 323, 44–51. [Google Scholar] [CrossRef] [Green Version]
  62. Harding, C.M.; Tracy, E.N.; Carruthers, M.D.; Rather, P.N.; Actis, L.A.; Munson, R.S. Acinetobacter baumannii strain M2 produces Type IV pili which play a role in natural transformation and twitching motility but not surface-associated motility. mBio 2013, 4, e00360-13. [Google Scholar] [CrossRef] [Green Version]
  63. Chen, R.; Lv, R.; Xiao, L.; Wang, M.; Du, Z.; Tan, Y.; Cui, Y.; Yan, Y.; Luo, Y.; Yang, R.; et al. A1S_2811, a CheA/Y-like hybrid two-component regulator from Acinetobacter baumannii ATCC17978, is involved in surface motility and biofilm formation in this bacterium. Microbiologyopen 2017, 6, e00510. [Google Scholar] [CrossRef] [PubMed]
  64. Elkins, J.G.; Hassett, D.J.; Stewart, P.S.; Schweizer, H.P.; McDermott, T.R. Protective role of catalase in Pseudomonas aeruginosa biofilm resistance to hydrogen peroxide. Appl. Environ. Microbiol. 1999, 65, 4594–4600. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Sun, D.; Crowell, S.A.; Harding, C.M.; De Silva, P.M.; Harrison, A.; Fernando, D.M.; Mason, K.M.; Santana, E.; Loewen, P.C.; Kumar, A.; et al. KatG and KatE confer Acinetobacter resistance to hydrogen peroxide but sensitize bacteria to killing by phagocytic respiratory burst. Life Sci. 2016, 148, 31–40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Darling, A.E.; Mau, B.; Perna, N.T. ProgressiveMauve: Multiple genome alignment with gene gain, loss and rearrangement. PLoS ONE 2010, 5, e11147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Kearse, M.; Moir, R.; Wilson, A.; Stones-Havas, S.; Cheung, M.; Sturrock, S.; Buxton, S.; Cooper, A.; Markowitz, S.; Duran, C.; et al. Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012, 28, 1647–1649. [Google Scholar] [CrossRef]
  68. Agrawal, S.; Arze, C.; Adkins, R.S.; Crabtree, J.; Riley, D.; Vangala, M.; Galens, K.; Fraser, C.M.; Tettelin, H.; White, O.; et al. CloVR-Comparative: Automated, cloud-enabled comparative microbial genome sequence analysis pipeline. BMC Genom. 2017, 18, 332. [Google Scholar] [CrossRef]
  69. Marchler-Bauer, A.; Bo, Y.; Han, L.; He, J.; Lanczycki, C.J.; Lu, S.; Chitsaz, F.; Derbyshire, M.K.; Geer, R.C.; Gonzales, N.R.; et al. CDD/SPARCLE: Functional classification of proteins via subfamily domain architectures. Nucleic Acids Res. 2017, 45, D200–D203. [Google Scholar] [CrossRef]
  70. Chen, L.; Zheng, D.; Liu, B.; Yang, J.; Jin, Q. VFDB 2016: Hierarchical and refined dataset for big data analysis--10 years on. Nucleic Acids Res. 2016, 44, D694–D697. [Google Scholar] [CrossRef]
  71. Iwashkiw, J.A.; Seper, A.; Weber, B.S.; Scott, N.E.; Vinogradov, E.; Stratilo, C.; Reiz, B.; Cordwell, S.J.; Whittal, R.; Schild, S.; et al. Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation. PLoS Pathog. 2012, 8, e1002758. [Google Scholar] [CrossRef]
  72. Loewen, P.C.; De Silva, P.M.; Donald, L.J.; Switala, J.; Villanueva, J.; Fita, I.; Kumar, A. KatG-mediated oxidation leading to reduced susceptibility of bacteria to kanamycin. ACS Omega 2018, 3, 4213–4219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Antibiotics 09 00328 g001 550
Figure 1. Whole genome alignment showing genomic rearrangements between the genomes of AB030 (top) and LAC-4 (bottom) (a); showing shared or unique CDS between AB030 and LAC-4 (b).
Figure 1. Whole genome alignment showing genomic rearrangements between the genomes of AB030 (top) and LAC-4 (bottom) (a); showing shared or unique CDS between AB030 and LAC-4 (b).
Antibiotics 09 00328 g001
Antibiotics 09 00328 g002 550
Figure 2. Functional categorization of the whole genomes of LAC-4 and AB030 using COG database.
Figure 2. Functional categorization of the whole genomes of LAC-4 and AB030 using COG database.
Antibiotics 09 00328 g002
Antibiotics 09 00328 g003 550
Figure 3. Presence of the ~9 Kb resistance island present in AB030 genome (red) (a). This island, missing in LAC-4 (blue), contains two aminoglycoside resistance genes and a β-lactam resistance gene (underlined). Comparison of the ~9 kb resistance island found in AB030 with those reported in A. baumannii and K. pneumoniae clinical isolates (b).
Figure 3. Presence of the ~9 Kb resistance island present in AB030 genome (red) (a). This island, missing in LAC-4 (blue), contains two aminoglycoside resistance genes and a β-lactam resistance gene (underlined). Comparison of the ~9 kb resistance island found in AB030 with those reported in A. baumannii and K. pneumoniae clinical isolates (b).
Antibiotics 09 00328 g003
Antibiotics 09 00328 g004 550
Figure 4. Genome-wide antibiotic resistance genes prediction using CARD database. * A mutation (81S→L) was found in the GyrA of AB030 and LAC-4. Percent identity to the reference gene is indicated in the shades of beige to maroon and the categories of the resistance genes are color-coded. #ParC has 84S→L in AB030, 88E→K in LAC-4, and 467S→G in both AB030 and LAC-4. @ RpsJ contains a 57V→L mutation in AB030.
Figure 4. Genome-wide antibiotic resistance genes prediction using CARD database. * A mutation (81S→L) was found in the GyrA of AB030 and LAC-4. Percent identity to the reference gene is indicated in the shades of beige to maroon and the categories of the resistance genes are color-coded. #ParC has 84S→L in AB030, 88E→K in LAC-4, and 467S→G in both AB030 and LAC-4. @ RpsJ contains a 57V→L mutation in AB030.
Antibiotics 09 00328 g004
Antibiotics 09 00328 g005 550
Figure 5. Genetic organization of AdeABC RND-efflux system and two-component system, AdeRS in AB030 (red) and LAC-4 (blue). The adeRS operon that encodes the regulator of the AdeABC system is missing in the LAC-4 genome.
Figure 5. Genetic organization of AdeABC RND-efflux system and two-component system, AdeRS in AB030 (red) and LAC-4 (blue). The adeRS operon that encodes the regulator of the AdeABC system is missing in the LAC-4 genome.
Antibiotics 09 00328 g005
Antibiotics 09 00328 g006 550
Figure 6. Bacterial burdens in lung (a), spleen (b), and blood (c). Mice (n = 5/group) were intranasally inoculated with AB030 and the type strain ATCC17978. The clinical signs were scored as indicated (d). The mice were sacrificed at 24 hours and their blood, lung, and spleen collected for quantitative bacteriology. The dotted lines in red indicate the limit of detection. Data for AB030 and ATCC17978 were compared with pooled data from 18 mice for LAC-4 (shown as gray horizontal bars) from four independent experiments. The bacterial burden data were analyzed by one-way ANOVA followed by post hoc Dunnett’s multiple comparison test.
Figure 6. Bacterial burdens in lung (a), spleen (b), and blood (c). Mice (n = 5/group) were intranasally inoculated with AB030 and the type strain ATCC17978. The clinical signs were scored as indicated (d). The mice were sacrificed at 24 hours and their blood, lung, and spleen collected for quantitative bacteriology. The dotted lines in red indicate the limit of detection. Data for AB030 and ATCC17978 were compared with pooled data from 18 mice for LAC-4 (shown as gray horizontal bars) from four independent experiments. The bacterial burden data were analyzed by one-way ANOVA followed by post hoc Dunnett’s multiple comparison test.
Antibiotics 09 00328 g006
Antibiotics 09 00328 g007 550
Figure 7. Biofilm formation by AB030 in comparison to LAC-4 and ATCC17978 (a). Organization of bap (biofilm-associated protein-encoding gene) in AB030 (red) and LAC-4 (blue) (b). There is insertion of an IS5 family transposases before the start codon of the bap gene in AB030 which may disrupt its transcription. Statistical analysis was carried out using one-way ANOVA with Tukey’s multiple comparison test. **** denotes p < 0.0001.
Figure 7. Biofilm formation by AB030 in comparison to LAC-4 and ATCC17978 (a). Organization of bap (biofilm-associated protein-encoding gene) in AB030 (red) and LAC-4 (blue) (b). There is insertion of an IS5 family transposases before the start codon of the bap gene in AB030 which may disrupt its transcription. Statistical analysis was carried out using one-way ANOVA with Tukey’s multiple comparison test. **** denotes p < 0.0001.
Antibiotics 09 00328 g007
Antibiotics 09 00328 g008 550
Figure 8. Motility of AB030 compared to that of LAC-4 and ATCC17978 (a). Organization of the csu operon in AB030 (red) and LAC-4 (blue) (b). Statistical analysis was carried out using the one-way (for motility assays) and two-way (for biofilm assays) analysis of variance (ANOVA) (****, p < 0.0001).
Figure 8. Motility of AB030 compared to that of LAC-4 and ATCC17978 (a). Organization of the csu operon in AB030 (red) and LAC-4 (blue) (b). Statistical analysis was carried out using the one-way (for motility assays) and two-way (for biofilm assays) analysis of variance (ANOVA) (****, p < 0.0001).
Antibiotics 09 00328 g008
Table
Table 1. Genome features of AB030 and LAC-4.
Table 1. Genome features of AB030 and LAC-4.
FeatureAB030LAC-4
Number of base pairs4,335,7933,954,354
G+C content39%39%
CDS (total)42003745
Genes (total)42963839
Genes (RNA)9694
Table
Table 2. A comparison of genomic islands (GIs) found in A. baumannii LAC-4 with those in A. baumannii AB030. Alignment of GIs is shown in Supplementary Figure S1.
Table 2. A comparison of genomic islands (GIs) found in A. baumannii LAC-4 with those in A. baumannii AB030. Alignment of GIs is shown in Supplementary Figure S1.
Genomic Islands in LAC-4Location in LAC-4 GenomeIsland Length (bp)AB030
CoverageSequence Identity
GI1 (Suppl. Figure S1a)120,830–133,65512825100100%
GI2 (Suppl. Figure S1b)547,857–581,62133764--
GI3 (Suppl. Figure S1c)788,377–800,9751259861%99%
GI4 (Suppl. Figure S1d)940,403–951,9201151778%99%
GI5 (Suppl. Figure S1e)1,229,550–1,257,9422839274%96%
GI6 (Suppl. Figure S1f)1,571,326–1,611,2253989962%94%
GI7 (Suppl. Figure S1g)1,730,338–1,741,0471070959%100%
GI8 (Suppl. Figure S1h)1,941,480–1,993,07651596--
GI9 (Suppl. Figure S1i)2,963,891–2,993,4112952048%94%
GI10 (Suppl. Figure S1j)3,028,724–3,058,4122968848%96%
GI11 (Suppl. Figure S1k)3,367,720–3,386,189184695%80%
GI12 (Suppl. Figure S1l)3,852,499–3,882,6763017758%100%

Share and Cite

MDPI and ACS Style

Singh, M.; De Silva, P.M.; Al-Saadi, Y.; Switala, J.; Loewen, P.C.; Hausner, G.; Chen, W.; Hernandez, I.; Castillo-Ramirez, S.; Kumar, A. Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030. Antibiotics 2020, 9, 328. https://doi.org/10.3390/antibiotics9060328

AMA Style

Singh M, De Silva PM, Al-Saadi Y, Switala J, Loewen PC, Hausner G, Chen W, Hernandez I, Castillo-Ramirez S, Kumar A. Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030. Antibiotics. 2020; 9(6):328. https://doi.org/10.3390/antibiotics9060328

Chicago/Turabian Style

Singh, Manu, P. Malaka De Silva, Yasser Al-Saadi, Jacek Switala, Peter C. Loewen, Georg Hausner, Wangxue Chen, Ismael Hernandez, Santiago Castillo-Ramirez, and Ayush Kumar. 2020. "Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030" Antibiotics 9, no. 6: 328. https://doi.org/10.3390/antibiotics9060328

APA Style

Singh, M., De Silva, P. M., Al-Saadi, Y., Switala, J., Loewen, P. C., Hausner, G., Chen, W., Hernandez, I., Castillo-Ramirez, S., & Kumar, A. (2020). Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030. Antibiotics, 9(6), 328. https://doi.org/10.3390/antibiotics9060328

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop